U.S. tariffs on pharmaceuticals could complicate an already complex supply chain
Drug companies could begin questioning whether to manufacture drugs or conduct clinical trials in Canada, says Life Sciences Ontario CEO.
Canada’s level of pharmaceutical drug exports pales in comparison to other products on the United States’ list of tariff targets, but experts say the impacts would still be significant because of the industry’s integrated and complex global supply chain.
Get Today's Headlines Newsletter
Wake up to the day's top political and policy headlines. Weekday Mornings.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
